CERU Stock News 6.49 05/13/2014 19:38:57 Cerulean Pharma Inc.

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cerulean Pharma Inc. (CERU) 6.49 $CERU

Cerulean Pharma Announces Exercise of Over-Allotment Option
GlobeNewswire - Wed May 07, 3:45PM CDT
Cerulean Pharma Inc. (Nasdaq:CERU) today announced that the underwriters for its initial public offering of common stock have exercised their over-allotment option and purchased an additional 1,069,715 shares. The additional shares were sold at the public offering price of $7.00 per share, before underwriting discounts. The closing occurred on May 7, 2014, bringing the total number of shares sold by Cerulean in the initial public offering to 9,569,715 shares and the total gross proceeds to approximately $67 million before underwriting discounts and offering expenses.

Fallopian Tube Cancer - Pipeline Review, H1 2014: 30 Companies and 37 Drugs Profiled
M2 - Wed May 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7chq8b/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Amgen Inc. - Boehringer Ingelheim GmbH - California Stem Cell, Inc. - Cell Therapeutics, Inc. - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Daiichi Sankyo Company, Limited - EGEN, Inc. - Eli Lilly and Company - GlaxoSmithKline plc - ImmunoGen, Inc. - Immunovaccine, Inc. - Incyte Corporation - Lee's Pharmaceutical Holdings Limited - MEI Pharma, Inc. - MabVax Therapeutics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OncoMed Pharmaceuticals, Inc. - Oncolytics Biotech Inc. - Oxford BioMedica plc - Pharma Mar, S.A. - Pharmacyclics, Inc. - Recepta Biopharma S.A. - Spectrum Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - TRION Pharma GmbH Drug Profiles: - pazopanib hydrochloride - trebananib - paclitaxel poliglumex - paclitaxel - MEK-162 - idronoxil - trabectedin - alisertib - dalantercept - elesclomol - TroVax - ramucirumab - pelareorep - nintedanib - catumaxomab - CRLX-101 - VTX-2337 - gimatecan - exatecan mesylate - RebmAb-100 - EGEN-001 - NSC-748933 - INCB-24360 - birinapant - rucaparib - metformin - Cancer Stem Cell Therapy - DPX-Survivac - ganetespib - pralatrexate For more information visit http://www.researchandmarkets.com/research/7c...opian_tube

Biotech IPOs Hit the Wall
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 28, 5:30PM CDT
While many investors ignore biotechs that have just gone public, waiting for them to mature, you should still keep an eye on the state of the IPO market, since it's a barometer for the risk investors are willing to take with established public...

Global Metastatic Renal Cell Carcinoma Therapeutics Pipeline Review 2014 - Analysis of 23 Companies & 34 Drug Profiles
M2 - Tue Apr 22, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jgdszp/metastatic_renal) has announced the addition of the "Metastatic Renal Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Renal Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Renal Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Renal Cell Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Renal Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Renal Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - Eli Lilly and Company - Novartis AG - Biocon Limited - Eisai Co., Ltd. - Exelixis, Inc. - Bionomics Limited - Jiangsu Hengrui Medicine Co., Ltd. - Panacea Biotec Limited - Rexahn Pharmaceuticals, Inc. - Debiopharm International S.A. - Acceleron Pharma, Inc. - Argos Therapeutics, Inc. - Cerulean Pharma, Inc. - Immutep S.A. - Syndax Pharmaceuticals, Inc. - TVAX Biomedical, Inc. - Kite Pharma, Inc. - Xiamen Amoytop Biotech Co., Ltd. - Inbiopro Solutions Pvt. Ltd. - Activartis Biotech GmbH - AlphaMab Co., Ltd Drug Profiles - cabozantinib (s)-malate - 177Lu-DOTA-cG250 - AGS-003 - AV0-113 - AZD-2014 - Anti-NY ESO-1 Lymphocytes Vaccine - Autologous Tumor Cell Vaccine [aldesleukin] - BNC-105-P - CRLX-101 - DC-AdGM-CAIX - Debio-0932 - Dendritic Cell Vaccine [aldesleukin] [bevacizumab] [interferon alfa-2b] - IBPM-002-BZ - IMP-321 - LY-2510924 - Mechanism of Action - Orellanine - Product Description - R&D Progress - RX-0201 - SHR-1020 - TVI-Kidney-1 - aldeluskin - bevacizumab biosimilar - bevacizumab biosimilar - bevacizumab biosmilar - dalantercept - decitabine romidepsin - entinostat - everolimus For more information visit http://www.researchandmarkets.com/research/jg...atic_renal

Cerulean Pharma Announces Closing of Initial Public Offering
GlobeNewswire - Tue Apr 15, 10:14AM CDT
Cerulean Pharma Inc. (Nasdaq:CERU) today announced the closing of its initial public offering of 8,500,000 shares of its common stock at a public offering price of $7.00 per share, before underwriting discounts.

Biotech IPOs Adamas, Cerulean Slump In Trading Debut
at Investor's Business Daily - Thu Apr 10, 3:02PM CDT
Adamas Pharmaceuticals (ADMS) and Cerulean Pharma (CERU) launched IPOs Thursday, two of four biotechs expected to debut this week. Adamas priced at 16, the low end of its range. In late afternoon trading, the stock was near 15.30 on the stock market...

Cerulean Pharma Announces Pricing of Initial Public Offering
GlobeNewswire - Thu Apr 10, 10:09AM CDT
Cerulean Pharma Inc. (Nasdaq:CERU) today announced the pricing of its initial public offering of 8,500,000 shares of its common stock at a public offering price of $7.00 per share, before underwriting discounts. In addition, Cerulean has granted the underwriters a 30-day option to purchase up to an additional 1,275,000 shares of common stock at the public offering price, less underwriting discounts. Cerulean's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the ticker symbol "CERU" today.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Chemours Legal Succession Gets a Long Transition Runway

Updated Category News Views 201

A corporate-law handoff rarely sets pulses racing, but this one deserves a proper look. Chemours is replacing its long-serving general counsel while keeping the departing executive in the building for four additional months. That is not flashy, and thank goodness for that. In a global chemicals company, legal leadership touches regulation, compliance, governance,...

Continue Reading
Nvidia Faces SEC Probe Report and New Lawsuit Stakes

Updated Category News Views 40

Silicon Valley's favorite growth machine has stumbled into the sort of fog investors hate most: regulatory questions, leadership upheaval, and a stock-price reaction with no clean answer attached. Reports cited in the lawsuit update say the Securities and Exchange Commission has opened a civil probe into NVIDIA's investor disclosures following former CEO Jensen Huang's...

Continue Reading
PSEG Long Island Warns Customers on QR Payment Scams

Updated Category News Views 131

Holiday panic is a thief's favorite crowbar, and Long Island households are plainly in the crosshairs. PSEG Long Island used Utility Scam Awareness Day on Nov. 18 to warn customers about impersonators demanding immediate payment under threat of a power shutoff. The central message, “Think Before You Scan,” is not flashy corporate wallpaper. It is practical advice for...

Continue Reading
AbbaDox Finds Follow-Up Scans Lost in the Shuffle

Updated Category News Views 22

A six-month recommendation has a nasty habit of disappearing beneath today’s emergencies. That is the unglamorous, important problem AbbaDox is trying to solve in outpatient radiology: not reading the scan, but making sure a future scan recommendation actually gets reviewed, ordered, and scheduled. For investors watching healthcare operations software, this is the sort...

Continue Reading
Teciem’s New CFO Puts Financial Discipline Behind Growth

Updated Category News Views 43

A finance chief moving continents is not decorative corporate wallpaper. Teciem’s decision to appoint Jesús Rueda Molins as chief financial officer says the company wants its next growth chapter run with more than product ambition and executive slogans. It wants somebody holding the purse strings who already knows the machinery, the customers and the people making the...

Continue Reading
Radiology Staffing Gap Deepens as Imaging Demand Rises

Updated Category News Views 112

An imaging order does not mean much if nobody is available to read it, and that plain operational fact sits at the center of Medicus Healthcare Solutions' 2026 report on the radiologist shortage. The report's projected gap of 2,450 full-time-equivalent radiologists in 2027 is troubling enough. Its estimate of a 4,130 FTE shortfall by 2032 is the part that should make...

Continue Reading
SK hynix Faces Fresh DRAM Collusion Risk for Investors

Updated Category News Views 102

A Memory Market Win Can Turn Sour Fast Nothing rattles a chip story quite like the word collusion showing up beside a judge’s ruling. SK hynix had been riding a powerful memory-market narrative, but investors got a blunt reminder on November 15, 2026: a proposed U.S. class action accusing SK hynix, Samsung Electronics, and Micron of restricting DRAM supply to raise...

Continue Reading
Vail’s Board Fight Puts Strategy Under a Sharp Lens

Updated Category News Views 105

Fresh snow does not make a boardroom dispute disappear. Vail Resorts has put out an investor presentation ahead of its December 14, 2026 annual meeting, asking shareholders to support all nine of management’s director nominees on its white proxy card. That is the formal message. The real message is plainer: NYSE:MTN knows this election has become a test of whether...

Continue Reading
Candel’s BLA Delay Puts Disclosure Timing Under Fire

Updated Category News Views 0

A December filing turned into a mid-2027 wait, and Candel shareholders absorbed the damage in one ugly trading session. On November 13, shares of Candel Therapeutics fell 26% after the company disclosed that its biologics license application, or BLA, for aglatimagene in prostate cancer was no longer expected in December 2026. The revised plan is to submit in the middle of...

Continue Reading
The Hanover Survey Puts Small-Business Trust on Trial

Updated Category News Views 275

A dark storefront can apparently erase goodwill faster than plenty of owners want to admit. The Hanover Insurance Group's 2026 Small Business Pulse Report found that 60% of surveyed consumers would temporarily buy from a competitor if their preferred small business shut unexpectedly. More than half would start looking elsewhere within a week. That is not a cute...

Continue Reading

Top 5 Most Recently Viewed Articles

TCL's Innovative Initiatives: Sustainability and Creativity Unite

Updated Category News Views 304

TCL's Commitment to Innovation and Sustainability At IFA 2024, TCL, a prominent global technology brand, showcased its unwavering dedication to innovation and sustainability. This year marks TCL's 14th consecutive appearance at the event, where the company highlighted two key initiatives: TCLGreen and TCLArt. These initiatives have attracted considerable attention as they...

Continue Reading
Western Metallica Closes Private Placement to Boost Copper Projects

Updated Category News Views 209

Western Metallica's Successful Private Placement Financing Western Metallica Resources Corp. (TSXV: WMS) has successfully completed its non-brokered private placement financing. This strategic decision allowed the company to issue a significant number of units at an appealing price point. By offering 10,833,345 units at $0.03 each, Western Metallica raised gross proceeds...

Continue Reading
Astrion's New Leadership Team Set to Drive Future Innovations

Updated Category News Views 250

Astrion Unveils Dynamic Executive Leadership Team Astrion, a leader in providing advanced engineering services and mission support to government sectors, has recently announced an exciting new executive leadership team. This strategic move aligns with their ongoing mission to deliver innovative solutions following the acquisition of Axient. With industry veteran Dave...

Continue Reading
Keyera Corp. Schedules Conference Call for Q3 2024 Results

Updated Category News Views 119

Keyera Corp. Schedules 2024 Q3 Results Conference Call Keyera Corp. has announced its timeline for the release of third-quarter results. Investors and interested parties are encouraged to take note of the important dates surrounding this announcement. When to Expect the Financial Results The financial results are set to be released before the market opens on November 14,...

Continue Reading
Netflix Partners with WWE to Revitalize Global Wrestling Fanbase

Updated Category News Views 411

Netflix and WWE Join Forces for a Live Streaming Revolution In an exciting new venture, Netflix has entered the world of live programming by teaming up with World Wrestling Entertainment (WWE) to stream its flagship show, "Raw." This collaboration marks a significant shift in how wrestling fans will experience their favorite matches, bringing the thrill of live...

Continue Reading